About this Research Topic
Neovascular retinal disease is a condition that results in the growth of abnormal blood vessels in the retina, mainly include age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). Retinal neovascularization (RNV) may lead to vitreous hemorrhage, tractional retinal detachment, neovascular glaucoma, and finally severe vision loss and blindness.
Inhibition of the proangiogenic factors is the main therapeutic mechanisms for blocking RNV. Several proangiogenic factors have been identified, include Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Platelet Derived Growth Factor (PDGF). In addition, Ang2, integrin αvβ3, erythropoietin and endothelin also had been reported as novel angiogenic factors that are involved in RNV. Among those proangiogenic factors, the development of anti-VEGF therapy is a breakthrough and are the first-line treatment strategy in neovascular retinal disease. However, it has some limitations. It requires frequent injections and is associated with systemic adverse events and complications. Additionally, some patients may develop resistance to anti-VEGF therapy. In further, it does not address other angiogenic factors that contribute to RNV.
This collection aims to collect scientific publications related to novel angiogenic factors which contribute to neovascular retinal diseases. The exploration of novel angiogenic factors could result in better understanding of RNV, and generation of novel therapy for neovascular retinal diseases.
Inhibition of the proangiogenic factors is the main therapeutic mechanisms for blocking RNV. Several proangiogenic factors have been identified, include Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Platelet Derived Growth Factor (PDGF). In addition, Ang2, integrin αvβ3, erythropoietin and endothelin also had been reported as novel angiogenic factors that are involved in RNV. Among those proangiogenic factors, the development of anti-VEGF therapy is a breakthrough and are the first-line treatment strategy in neovascular retinal disease. However, it has some limitations. It requires frequent injections and is associated with systemic adverse events and complications. Additionally, some patients may develop resistance to anti-VEGF therapy. In further, it does not address other angiogenic factors that contribute to RNV.
This collection aims to collect scientific publications related to novel angiogenic factors which contribute to neovascular retinal diseases. The exploration of novel angiogenic factors could result in better understanding of RNV, and generation of novel therapy for neovascular retinal diseases.
Keywords: Novel angiogenic factors in Neovascular retinal disease
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
